Prolactinoma associated with Primary Hyperaldosteronism: Is there a connection between the two entities?
PDF (Español (España))
HTML (Español (España))



How to Cite

Fragozo-Ramos, M. C., Gómez-Galvis, L. V., Gómez-Sierra, V., & Román-González, A. (2023). Prolactinoma associated with Primary Hyperaldosteronism: Is there a connection between the two entities?. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 10(3).


Background: Prolactinomas are the most common type of pituitary tumor. Patients with prolactinomas present with signs and symptoms of hypogonadism and galactorrhea. Primary aldosteronism (PA) is an underdiagnosed cause of hypertension, characterized by autonomous aldosterone secretion. The concomitance of these two syndromes has been infrequently reported in the literature.

Purpose: To present a case of prolactinoma-PA coexistence in order to highlight the co-occurrence of both entities and to expose the potential pathophysiological link between hyperprolactinemia/prolactinoma and PA.

Case presentation: 38-year-old woman with a history of several years of oligomenorrhea without galactorrhea. Initial biochemistry with hyperprolactinemia and MRI of the sellar region revealed a prolactinoma. During follow-up, the patient had hypertension that was difficult to control, a secondary cause was explored, which revealed an aldosterone/plasma renin activity ratio of 232 ng/dL/ng/mL/h in presence of a 10 mm left adrenal adenoma, these findings confirmed the diagnosis of primary hyperaldosteronism.

Discussion and conclusion: The coexistence of these two findings is a condition rarely described in the literature, and it is hypothesized that elevated PRL concentrations could play a role in the pathogenesis of PA in patients who are not part of the Multiple Endocrine Neoplasia Type 1 (MEN1) genetic syndrome.
PDF (Español (España))
HTML (Español (España))


Vaidya A, Hundemer GL, Nanba K, Parksook WW, Brown JM. Primary Aldosteronism: State-of-the-Art Review. Am J Hypertens. 2022 dic. 8;35(12):967-88.

Young WF. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019 febr.;285(2):126-48.

Nakamura Y, Yamazaki Y, Felizola SJ, Ise K, Morimoto R, Satoh F, et al. Adrenocortical Carcinoma: Review of the Pathologic Features, Production of Adrenal Steroids, and Molecular Pathogenesis. Endocrinol Metab Clin North Am. 2015 jun.;44(2):399-410.

Jackson B, Valentine R, Wagner G. Primary Aldosteronism Due To a Malignant Ovarian Tumour. Aust N Z J Med. 1986 febr.;16(1):69-71.

Hundemer GL, Vaidya A. Primary Aldosteronism Diagnosis and Management: A Clinical Approach. Endocrinol Metab Clin North Am. 2019 dic.;48(4):681-700.

Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab. 2019;33(2).

Gregerson KA. Prolactin: Structure, function, and regulation of secretion. Knobil Neill’s Physiol Reprod. 2006;80(4):1703-26.

Halperin Rabinovich I, Cámara Gómez R, García Mouriz M, Ollero García-Agulló D. Guía clínica de diagnóstico y tratamiento del prolactinoma y la hiperprolactinemia. Endocrinol y Nutr. 2013;60(6):308-19.

Carty DM, Harte R, Drummond RS, Ward R, Magid K, Collier D, et al. AIP variant causing familial prolactinoma. Pituitary. 2021;24(1):48-52.

Schernthaner-Reiter MH, Trivellin G, Stratakis CA. MEN1, MEN4, and Carney Complex: Pathology and Molecular Genetics. Neuroendocrinology. 2016 febr. 1;103(1):18-31.

Demura R, Naruse M, Isawa M, Onoda N, Naruse K, Yamakado M, et al. A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: Differences in dopaminergic regulation of PRL and aldosterone secretion. Endocrinol Jpn. 1992;39(2):169-76.

Holland OB, Gomez-Sanchez CE, Kem DC, Weinberger MH, Kramer NJ, Higgins JR. Evidence against prolactin stimulation of aldosterone in normal human subjects and patients with primary aldosteronism, including a patient with primary aldosteronism and a prolactin-producing pituitary microadenoma. J Clin Endocrinol Metab. 1977 nov.;45(5):1064-76.

Jia M, Yu H, Liu Z, He M, Zhong S, Xu X, et al. Normotensive presentation in primary aldosteronism: A report of two cases. J Renin Angiotensin Aldosterone Syst. 2021;22(1).

Demura M, Yoneda T, Karashima S, Higashikata T, Mabuchi H, Kawano M, et al. A possible new syndrome with double endocrine tumors in association with an unprecedented type of familial heart-hand syndrome: A Case report. J Med Case Rep. 2010;4(1).

Petersenn S. Biochemical diagnosis in prolactinomas: some caveats. Pituitary. 2020;23(1):9-15.

Saleem M, Martin H, Coates P. Prolactin biology and laboratory measurement: An update on physiology and current analytical issues. Clin Biochem Rev. 2018;39(1):3-16.

Maiter D. Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2019;109(1):42-50.

Gorvin CM. The prolactin receptor: Diverse and emerging roles in pathophysiology. Diverse and emerging roles in pathophysiology.J Clin Transl Endocrinol. 2015;2(3):85-91.

Funes Hernandez M, Bhalla V. Underdiagnosis of Primary Aldosteronism: A Review of Screening and Detection. Am J Kidney Dis. 2023 mzo. 23.

Brown JM, Robinson-Cohen C, Luque-Fernandez MA, Allison MA, Baudrand R, Ix JH, et al. The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study. Ann Intern Med. 2017 nov. 7;167(9):630-41.

Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016 my.;101(5):1889-916.

Turcu AF, Yang J, Vaidya A. Primary aldosteronism - a multidimensional syndrome. Nat Rev Endocrinol. 2022 nov.;18(11):665-82.

Burrello J, Amongero M, Buffolo F, Sconfienza E, Forestiero V, Burrello A, et al. Development of a Prediction Score to Avoid Confirmatory Testing in Patients with Suspected Primary Aldosteronism. J Clin Endocrinol Metab. 2021 mzo. 25;106(4):e1708-16.

Zhang M, Bian G, Tian J, Yang W, Wang X, Chi C. Assessment of biochemical outcomes in patients with primary aldosteronism after adrenalectomy based on CT scan diagnosis of unilateral adenoma without adrenal vein sampling. Front Oncol. 2022 nov. 16;12.

Dekkers T, Prejbisz A, Kool LJ, Groenewoud HJ, Velema M, Spiering W, et al. Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: an outcome-based randomized diagnostic trial. Lancet Diabetes Endocrinol. 2016 sept. 1;4(9):739-46.

Glasow A, Breidert M, Haidan A, Anderegg U, Kelly PA, Bornstein SR. Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. J Clin Endocrinol Metab.1996;81:3103-11.

Williams TA, Dietz AS, Theodoropoulou M, Riester A, Fischer E, Burrello J, et al. Coexisting prolactinoma and primary aldosteronism: Is there a pathophysiological link? J Clin Endocrinol Metab. 2015;100(9):E1262-9.

Ohara N, Kobayashi M, Yoneoka Y, Hasegawa G, Aoki Y, Nakamura Y, et al. Primary Aldosteronism Presenting with Hypertension Five Days after Delivery: A Case Report and Literature Review. Intern Med. 2022;61(4):507-12.

Parazzoli C, Favero V, Morelli V, Aresta C, Chiodini I, Falchetti A. Primary Aldosteronism and microprolactinoma: A new syndromic variant? Endocr Abstr. 2022;81:6.

Gould E, Albores-Saavedra J, Shuman J. Pituitary prolactinoma, pancreatic glucagonomas, and aldosterone-producing adrenal cortical adenoma: A suggested variant of multiple endocrine neoplasia type I. Hum Pathol. 1987;18(12):1290-3.

Doumith R, Luc de Gennes J, Cabane JP, Zygelman N. Pituitary prolactinoma, adrenal aldosterone-producing adenomas, gastric schwannoma and colonic polyadenomas: A possible variant of multiple endocrine neoplasia (MEN) type I. Acta Endocrinol (Copenh). 1982;100(2):189-95.

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018 en. 1;6(1):51-9.

Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018 ag. 1;3(8):768-74.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2023 Revista Colombiana de Endocrinología, Diabetes & Metabolismo




Download data is not yet available.